HR 1548 · 111th Congress 2009–2011, ended

Pathway for Biosimilars Act

Latest action · Mar 18, 2009 Referred to the Subcommittee on Health.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedMar 17, 2009
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Pathway for Biosimilars Act - Amends the Public Health Service Act to allow a person to submit an application for licensure of a biological product based on its similarity to a licensed biological product (the reference product).

Requires the Secretary of Health and Human Services to approve the application if: (1) the biological product is biosimilar to the reference product with respect to each condition of use for which the reference product is approved; and (2) the applicant consents to the inspection of the facility that is the subject of the application.

Sets forth requirements for a determination by the Secretary that a biological product is interchangeable with a reference product.

Prohibits a biological product from being evaluated against more than one reference product.

Prohibits licensure under this Act of a biological product containing specified agents or toxins or a schedule I or II controlled substance unless the Secretary determines there would be no increased risk to the security or health of the public from licensing such a biological product.

Prohibits the Secretary from making approval of an application under this Act effective until 12 yeas after the date on which the reference product was first licensed.

Provides for confidentiality of information received pursuant to this Act.

Sets forth provisions governing patent infringement actions related to this Act.

Deems as patent infringement the submission of a statement under this Act by the applicant setting forth reasons why the making, use, or sale of the biosimilar product would not infringe the patent, or why the patent is invalid or unenforceable, if the purpose of such submission is to obtain approval to engage in the commercial manufacture, use, or sale before the expiration of such patent.

Cosponsors 149

Members who signed on, in the order they did. Signatures ran from Mar 17, 2009 to Nov 3, 2009; 43 are original cosponsors, there from the day it was introduced.

SeatCosponsorSigned on
D-WAAdam SmithOriginalMar 17, 2009
D-INBaron P. HillOriginalMar 17, 2009
D-MABill DelahuntOriginalMar 17, 2009
D-INBrad EllsworthOriginalMar 17, 2009
R-CABrian P. BilbrayOriginalMar 17, 2009
R-PACharles W. DentOriginalMar 17, 2009
R-CADarrell IssaOriginalMar 17, 2009
R-CADavid DreierOriginalMar 17, 2009
R-CADevin NunesOriginalMar 17, 2009
D-NYEdolphus TownsOriginalMar 17, 2009
D-CAEllen O. TauscherOriginalMar 17, 2009
R-MIFred UptonOriginalMar 17, 2009
D-TXGene GreenOriginalMar 17, 2009
D-MAJames P. McGovernOriginalMar 17, 2009
D-WAJay InsleeOriginalMar 17, 2009

Committees 2

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Mar 17, 2009
Health Subcommittee
Referred Mar 18, 2009
HouseJudiciary Committee
Referred Mar 17, 2009

Actions 6

Everything that happened, newest first.

  1. Mar 18, 2009Referred to the Subcommittee on Health.
  2. Mar 17, 2009Introduced in House
  3. Mar 17, 2009Sponsor introductory remarks on measure. (CR E687-688)
  4. Mar 17, 2009Referred to House Energy and Commerce
  5. Mar 17, 2009Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  6. Mar 17, 2009Referred to House Judiciary

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Printed hearings 3

Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.

NumberHearingCommitteeHeld
Serial No. 111-73BIOLOGICS AND BIOSIMILARS: BALANCING INCENTIVES FOR INNOVATION256 pagesJudiciary CommitteeJul 14, 2009
Serial No. 111-54COMPREHENSIVE HEALTH CARE REFORM DISCUSSION DRAFT1,055 pagesEnergy and Commerce CommitteeJun 23, 2009–Jun 25, 2009
Serial No. 111-46EMERGING HEALTH CARE ISSUES: FOLLOW-ON BIOLOGIC DRUG COMPETITION289 pagesEnergy and Commerce CommitteeJun 11, 2009

CRS reports 1

Congressional Research Service work that CRS links to this bill or the law it became, newest first.

Cite it 1

Products on other subjects that cite it, usually among other measures.

ProductTitleKindPublished
RL34045FDA Regulation of Follow-On Biologics ArchivedReportApr 26, 2010

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes.
Short Titles as Introduced
Pathway for Biosimilars Act

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Mar 17, 2009Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.